Stille AB
The answer first
Does Stille beat the market?
Yes, Stille has beaten the market over the last year.
The ranking · Quality, value and trend combined
Better than 88% of Nordic stocks
- Quality96
- Value32
- Trend83
No. 13 of 195 in healthcare
Expectations in the price
High expectations
For the share to return about 9% a year from today's price, the cash Stille keeps must grow about 14% a year for 10 years.
Max for seven days
Follow Stille with AuroraAurora lets you know at the next report. No card.
Both with dividends. Figures as of 18 November 2026. General analysis, not personal advice.
Follow your thesis
Ask Aurora about Stille
Your first answer is free, no account needed.
Do you own Stille, or are you thinking about it?
See it next to the rest of your portfolio, or build your first one with Stille and a few more. Free, no card.
Super Stock+44.6%In short
- Stille has risen 43.8% over the past year, including dividends.
- Overall, Stille ranks better than 88% of Nordic stocks on quality, value and trend.
- The largest fall over the past three years was 46.1%. The price is 7.8% below its peak now.
What do analysts think of Stille?
Quality, value and trend
Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.
Quality, value and trend together. Better than 88% of Nordic stocks.
No. 13 of 195 in healthcare
High A solid company: it earns well on its money and has healthy finances.
No. 15 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50
- Debt to equityBorrowings divided by equity0.08
- Asset turnoverSales divided by everything the company owns0.61
- Return on equityProfit divided by equity+11.9%
- Cash conversionOperating cash flow divided by profit0.91
The ranking is built on equity ratio, ROA and how steadily profit grows.
Low High price: buyers pay a lot today, often because they expect growth.
No. 72 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50
- P/BPrice divided by equity2.8
- P/SPrice divided by sales3.2
- P/EPrice divided by earnings23.4
- P/CFPrice divided by operating cash flow25.7
The ranking is built on P/E, P/B and P/S.
High Tailwind in the share price: it has risen more than most over the last year.
No. 38 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50
- 3 months+9.7%
- 6 months−1.0%
- 9 months+35.0%
- 12 months+43.8%
The ranking is built on 3, 6 and 12–1 months.
Return and risk
Return with dividends reinvested.
The funds that own Stille
3 funds we follow own Stille. The share is how much of the fund the stock makes up.
- Norway1
- Sweden2
From the funds' latest known holdings.
About Stille
Stille AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 240 employees.
Stille AB (publ) develops, manufactures, and distributes medtech products in Sweden, Germany, the United Kingdom, Switzerland, North America, the United States, and internationally. It operates through the Surgical Instruments and Surgical Tables segments. The Surgical Instruments segment offers surgical scissors, including SuperCut, eye, blepharoplasty, operating, vascular, tenotomy, and face-lift scissors; colon, gall duct, multi-purpose, tangential occlusion, peripheral vascular, and anastomosis clamps; skin and nerve hooks, retractors, rib spreaders, self-retaining and trachea retractors, and nasal specula; and dressing, diathermy, knot-holding, tissue, iris, dura, and vascular forceps u…


See the full analysis of Stille.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
Free forever · No card